ARDT
Ardent Health Partners, LLC
ARDT's fundamentals are mixed, but it looks expensive: trading at 17x earnings, about twice its usual 9.0x. Analysts expect strong earnings growth.
ARDT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
ARDT's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ARDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $6.75 | -62% |
| Fair | 9x | $9.25 | -48% |
| Forward | 15x | $17.68 | — |
| Current | 17x | $17.68 | — |
| Expensive | 20x | $20.97 | +19% |
Historical ranges are pointers, not guarantees.
ARDT's PE is in its expensive range at 17x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
ARDT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect ARDT's earnings to grow and its profitability to improve, with its revenue holding steady.
ARDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.19 | +16% |
| Q3 2026 | $1.03 | -30% |
| Q2 2026 | $0.55 | -70% |
| Q1 2026 | $0.95 | -42% |
| Q4 2025 | $0.96 | -38% |
| Q3 2025 | $1.47 | +119% |
| Q2 2025 | $1.83 | +190% |
| Q1 2025 | $1.65 | +217% |
| Q4 2024 | $1.55 | +343% |
ARDT's earnings per share have fallen from their peak: $1.03 over the past year, against $1.83 in mid-2025.
ARDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +3.1% |
| Q2 2026 | $1.6B | -1.4% |
| Q1 2026 | $1.6B | +7% |
| Q4 2025 | $1.6B | -0.1% |
| Q3 2025 | $1.6B | +8.8% |
| Q2 2025 | $1.6B | +12% |
| Q1 2025 | $1.5B | +4% |
| Q4 2024 | $1.6B | +19% |
ARDT's revenue grew through 2024 and has held roughly level since: $1.6B last quarter, up 3.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5% | +5.1 points |
| Q2 2026 | 2.7% | -4.8 points |
| Q1 2026 | 4.7% | -0.3 points |
| Q4 2025 | 5.8% | -4.7 points |
| Q3 2025 | -0.1% | -4.1 points |
| Q2 2025 | 7.4% | +1.8 points |
| Q1 2025 | 5% | -0.3 points |
| Q4 2024 | 10% | -2.4 points |
ARDT's operating margin was 5% last quarter, up 5.1 points from the same quarter a year ago.
ARDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $121.9M | -21% |
| Q2 2026 | $196.7M | +67% |
| Q1 2026 | -$60.2M | -$35.4M |
| Q4 2025 | $223.4M | +87% |
| Q3 2025 | $154.4M | +72% |
| Q1 2025 | -$24.8M | +$13.7M |
| Q4 2024 | $119.6M | +1090% |
| Q3 2024 | $89.7M | +41% |
ARDT generated $482M in free cash flow over the past year, up 31% from the year before.
ARDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -1.3M shares |
| 1 year | +0.3% | +478K shares |
| 3 years | +0.5% | +741K shares |
| 5 years | +86% | +65.7M shares |
ARDT has 142M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11M |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2018 | — |
| Q3 2018 | — |
ARDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 1.0x | Healthy |
| Q1 2026 | 1.1x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.0x | Healthy |
| Q1 2024 | 5.1x | High |
| Q4 2023 | 5.5x | High |
ARDT's net debt is less than a year of its operating earnings (EBITDA).
ARDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 82.1 | Overbought |
| Stochastic | 88.7 | Overbought |
ARDT's weekly RSI is 82 (overbought) and its Stochastic is 89 (overbought).
ARDT PE vs Healthcare Sector
| Metric | ARDT | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 75 | 54 | 21 pts above |
ARDT is trading at 17x earnings, a 34% discount to the Healthcare sector's median of 26x.
ARDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.9 | 37% above |
| 20 week MA | $11.6 | 52% above |
| 50 week MA | $10.1 | 74% above |
| 100 week MA | $11.8 | 50% above |
ARDT is in an uptrend: it's above all four of its weekly moving averages, and 50% above its 100-week average.
ARDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $17.3 | $16.9 | -2.3% |
| 2025 | $16.9 | $9.22 | -45% |
| 2026 YTD | $9.22 | $17.7 | +92% |
ARDT has finished every year since 2024 lower, and it's up 92% so far in 2026.